港股市場個股詳情

09926 康方生物

添加自選

49.250
+0.250+0.51%

交易中 05/06 14:10 (北京)

426.43億總市值19.05市盈率TTM

康方生物股票討論區

登錄發表評論

Moomoo AI

03/21 07:14

Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.

Akeso, Inc. Just Recorded A 8.5% EPS Beat: Here's What Analysts Are Forecasting Next

Moomoo AI

03/15 06:41

Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.

Akeso, Inc.'s (HKG:9926) 25% Price Boost Is Out Of Tune With Revenues

Spinee

01/17 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$恒生指數(800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $榮昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三葉草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亞生物(01873.HK)$ ...

Moomoo AI

2023/12/28 10:11

Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues

Moomoo AI

2023/11/16 07:43

Akeso's strong net cash position and high liquidity suggest a low risk in its debt usage. The large conversion rate of EBIT to free cash flow also signals a positive financial health and potential profitability.

Is Akeso (HKG:9926) A Risky Investment?

ETFWorldSavior

2023/06/08 10:42

專欄Anxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...

BrandonnW

2021/10/08 16:42

$康方生物(09926.HK)$ Excellent clinical data, focus on product launch and data disclosure
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.

101712985

2021/10/07 10:11

$康方生物(09926.HK)$ 幾個月都木有新的評論了，這隻股票是死掉了嗎？

已翻譯

暫無評論

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

港股

綜合熱度